Dexcom Inc.,
biotech company specializing in continuous glucose monitoring systems, has been the focus of news recently for various reasons. Most significant is the filing of a securities fraud
class action lawsuit against the firm, affecting DXCM investors. There are allegations the company
misled investors regarding sales force changes and its financial outlook. Despite this,
Legal & General Group Plc and
APG Asset Management N.V. have increased their stakes in Dexcom. The company saw a decline in Q2, attributed to disruptive sales force changes.
Nevertheless, Dexcom's
G7 CGM system has seen increased coverage and their Q2 earnings have surpassed estimates. Their
G7 CGM Coverage expanded for Quebec residents, and the firm is preparing for its third quarter 2024 earnings release. Despite
revenue misses, analysts are debating whether the firm is a
'Millionaire Maker'. However, some advise caution and recommend holding instead of buying. Dexcom also faced a major drop after cutting its full-year sales forecast, and their share price has seen a drastic decline.
Second quarter 2024 financial results revealed unexpected earnings, leading to a reduction in company guidance.
Dexcom DXCM News Analytics from Wed, 20 Mar 2024 07:00:00 GMT to Sun, 29 Sep 2024 20:00:00 GMT -
Rating -8
- Innovation 4
- Information 5
- Rumor -5
